INTRODUCTION
• Renal osteodystrophy (ROD) and vascular calcification (VC) are integral components of chronic kidney disease-mineral/bone disorder (CKD-MBD). CKD-MBD is strongly associated with greatly increased morbidity and mortality in end-stage kidney disease (ESKD). 1 • Activin A is a transforming growth factor-β superfamily protein that is found at high levels in bone; its signaling is through the type II activin A receptor (ActRIIA). [2] [3] [4] Inhibin, an inhibitor of activin A signaling, is produced in the ovaries and stimulates bone growth. 2, 5 Decreased inhibin expression is associated with post-menopausal bone loss. 5 -Non-clinical studies suggest that RAP-011 (the murine ActRIIA-IgG1 ligand trap that inhibits ActRIIA signaling) modulates the balance between bone formation and bone resorption activity by blocking signaling through the ActRIIA receptor. 2, 6, 7 -In a 5/6 nephrectomy mouse model of CKD that exhibits bone loss, bone mass measurements were significantly improved with 8 weeks of RAP-011 treatment, compared with the control mice. 6 • In a mouse model of ldlr-/-high-fat fed, 5/6 nephrectomy for VC, RAP-011 inhibited bone resorption and increased bone volume. RAP-011 also inhibited Smad-dependent signaling, blocked aortic osteoblastic transition, increased vascular smooth muscle protein levels, and decreased CKD-stimulated VC. 8 These effects appear to be mediated by RAP-011 inhibition of CKD-stimulated endothelial to mesenchymal transition. 9 • Sotatercept (ACE-011), a human ActRIIA-IgG1 ligand trap that inhibits ActRIIA signaling, improved total hip bone mineral density (BMD) with a 2.4% increase compared with a 0.7% decrease with placebo after 4 months in a post-menopausal healthy volunteer clinical trial.
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• Sotatercept is being studied in subjects on hemodialysis (HD) for the correction of anemia and improvement of measures of CKD-MBD. Sotatercept blocks activin A signaling and may reduce osteoclastogenesis, promote osteoblast maturation in bone, and reduce arterial osteoblastic transition. 8, 9 • The current exploratory analysis in HD subjects evaluated the effect of sotatercept on BMD and VC using quantitative computed tomography (QCT) [10] [11] [12] and expands the dataset.
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• At the time of abstract submission, enrollment in a sotatercept dose group using a 14-day dose cycle was ongoing.
• Interim results for safety and hemoglobin (Hb) effects are presented elsewhere.
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METHODS
• In an ongoing study of sotatercept in HD subjects for the correction of anemia, subjects responding to an erythropoietin-stimulating agent (ESA) were washed out of their ESA effect until Hb was <10 g/dL, and then randomized (3:1) to receive escalating dose levels of SC sotatercept (0.3 mg/kg, 0.5 mg/kg, or 0.7 mg/kg) or placebo every 28 days for up to 8 dose cycles. The study design and dosing are described in detail elsewhere.
14 Treatment failures (Hb <9 g/dL) were treated with ESA and/or red blood cell transfusion (rescue therapy).
• QCT of the hip, lumbar spine, and abdominal aorta was obtained at baseline and after the 225-day treatment phase.
-Trabecular volumetric BMD (vBMD) (mg/cm 3 ) was determined for 2 vertebrae within L1-4 (typically L1-2).
-The left proximal femurs were analyzed for vBMD of the cortical, trabecular, and integral bone compartments of the total hip, femoral neck, and trochanteric regions.
-VC of the abdominal aorta was assessed using software that semi-automatically segmented the area and volume of calcifications within the region adjacent to the top of L1 through the bottom of L4. The number and location of slices was maintained across visits per subject. Agatston and square root transformed volumetric scores were determined as described elsewhere.
10,11
Lower total Agatston and square root transformed total volume scores (mm 3 ) indicate lower levels of VC.
-All image quality control and blinded analyses were performed centrally by PAREXEL imaging (PAREXEL International Corp, Waltham, MA).
-Results are based on all available data from the 21 subjects who had paired QCT assessments.
RESULTS
Subjects
• A total of 35 subjects were randomized and received ≥1 dose of study medication ( Table 1) . • The subject disposition is shown in Figure 1 , including the subjects with paired QCT measurements at baseline and Day 225.
-Most subjects who were discontinued from study treatment had treatment failure requiring rescue (generally because of Hb <9 g/dL; most common in the placebo and sotatercept 0.3 mg/kg groups); no subject discontinued treatment because of an adverse event (AE).
-Of the 21 subjects with paired QCT measurements, 12 required rescue therapy due to Hb treatment failure during the treatment phase, 9 of whom required rescue within the first 3 dose cycles.
• Among subjects with paired QCT measurements, baseline demographic and clinical characteristics were generally similar across treatment groups ( Table 2) ; however, there was a substantially longer time on dialysis in the placebo group, which was also the youngest group. There were also differences between groups in baseline biomarker and Agatston scores ( Table 3 ). 
Safety Assessments
• The safety findings from this study are described in detail elsewhere. 14 • Serious AEs were generally considered unrelated to the study drug, did not lead to discontinuation, and resolved with continued therapy. No deaths were reported in the sotatercept groups.
• AEs were mostly mild or moderate in severity, unrelated to the study drug, relatively similar between treatment groups, and generally consistent with subjects' medical histories.
• In the first 28-day dose cycle and during the 225-day treatment phase, home blood pressure measurements showed no consistent or dose-dependent changes from baseline among subjects in any of the treatment groups.
QCT VC Measurements
• The changes from baseline in abdominal aorta total Agatston scores are provided in Table 4 . The proportion of subjects with <15% progression in abdominal aorta total Agatston scores Change from baseline square root of total volume, mm QCT Volumetric BMD Measurements
• Table 5 provides the percent change from baseline in femoral neck cortical and lumbar spine trabecular volumetric BMD measurements. Note: The n reflects the number of randomized subjects with paired QCT assessments; actual number of subjects available for each parameter may vary.
• Proportions of subjects with >2% gain in femoral neck cortical BMD were determined 16 ; sotatercept treatment is associated with increases in the proportion of subjects with a >2% increase in femoral neck cortical bone ( Table 5 and Figure 3 ).
• In high-turnover ROD, trabecular bone mass increases, as measured by lumbar spine trabecular BMD, without a reduction in vertebral fracture rates in ESKD compared with the general population. 12, 17 In this setting, the increased trabecular bone mass is of poor quality. 18 Sotatercept appears to slow the increase in trabecular bone mass in the lumbar spine, compared with placebo ( Table 5 ). 
CONCLUSIONS
• Based on baseline biomarker data, subjects in this study tended to have high-turnover ROD. The placebo group had changes as expected for high-turnover ROD: decreased cortical bone mass, increased trabecular bone mass, and increased VC that occurred at a rate similar to other large studies in ESKD. 15 • In this small interim dataset evaluating exploratory QCT data measured at baseline and Day 225 (after up to eight 28-day dose cycles), there is an apparent effect of sotatercept on multiple parameters of CKD-MBD, including slowing progression of VC, increasing femoral neck cortical bone mass, and slowing the increase in trabecular bone mass in the lumbar spine. Bone histomorphometry data are required to better characterize the effects on lumbar spine BMD.
• The clinical findings of less VC and increase in bone mass are consistent with the histologic findings in the mouse model of ldlr-/-high-fat fed, ablative CKD-3 (5/6 nephrectomy) for VC. 8 • Important differences in baseline characteristics may influence these results; for example, the placebo group had the longest length of time on dialysis, the highest bone turnover biomarkers, and higher baseline Agatston scores. Conversely, the placebo group had the lowest use of calcium-based phosphate binders, and their PTH decreased through the study to levels more similar to the other groups.
• Sotatercept may be able to address significant unmet needs for the treatment of CKD-MBD in ESKD, while also increasing Hb.
